Company news
Keros Therapeutics, Inc. (NASDAQ:KROS) news
Keros Therapeutics, Inc. news releases on 6ix. Latest, Jun 4, 2024: Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
Press releases — page 2
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
June 3, 2024
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 2, 2024
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
May 27, 2024
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
May 13, 2024
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 7, 2024
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
March 13, 2024
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
March 4, 2024
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
January 28, 2024
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
January 8, 2024
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
January 2, 2024
Keros Therapeutics Announces Proposed Public Offering of Common Stock
January 2, 2024
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
January 2, 2024
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
December 10, 2023
Keros Therapeutics to Present at Upcoming Healthcare Conferences
November 6, 2023
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results
November 5, 2023
Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition
November 1, 2023
Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society
October 3, 2023
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 6, 2023
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
July 23, 2023
Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference
June 11, 2023
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association
June 8, 2023
Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference
June 6, 2023
Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference
May 21, 2023
Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association
May 10, 2023
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results
May 3, 2023
Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors
April 18, 2023
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
March 2, 2023
Keros Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
February 28, 2023
Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 6, 2023
Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition
December 11, 2022
Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions
November 6, 2022
Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047
November 2, 2022
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
November 2, 2022
Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting
September 11, 2022
Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 5, 2022
Keros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting
September 5, 2022
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 3, 2022
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions
June 12, 2022
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association
June 9, 2022
Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers
May 17, 2022
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
May 16, 2022
Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association
May 11, 2022
Keros Therapeutics Reports First Quarter 2022 Financial Results
May 4, 2022
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results
March 8, 2022
Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022
Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer
January 30, 2022
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition
December 12, 2021
Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China
December 12, 2021
Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 21, 2021